2015
DOI: 10.7860/jcdr/2015/12362.5816
|View full text |Cite
|
Sign up to set email alerts
|

Synchronous Diffuse Large B-Cell Lymphoma and Malignant Clonal Plasma Cells in Bone Marrow As Primary Presentation: A Diagnostic and Therapeutic Challenge

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 7 publications
0
1
0
Order By: Relevance
“…The most commonly reported double malignancies are solid tumors with hematological neoplasms, such as gastric cancer with diffuse large B-cell lymphoma (DLBCL), lung adenocarcinoma with chronic myeloid leukemia, colon cancer with myeloma, and lung cancer with myeloma [3]. However, synchronous presentation of two hematologic neoplasms is extremely rare and reported generally as myeloproliferative diseases (MPDs) with lymphoproliferative diseases [3], and the combinations were as follows: concomitant histiocytic sarcoma and DLBCL [4], DLBCL with myeloma [5], mantle cell lymphoma with chronic lymphocytic leukemia (CLL) [6,7], and DLBCL with Hodgkin's lymphoma [8,9], MPDs with CLL, and MPDs with hairy cell leukemia [10].…”
Section: Discussionmentioning
confidence: 99%
“…The most commonly reported double malignancies are solid tumors with hematological neoplasms, such as gastric cancer with diffuse large B-cell lymphoma (DLBCL), lung adenocarcinoma with chronic myeloid leukemia, colon cancer with myeloma, and lung cancer with myeloma [3]. However, synchronous presentation of two hematologic neoplasms is extremely rare and reported generally as myeloproliferative diseases (MPDs) with lymphoproliferative diseases [3], and the combinations were as follows: concomitant histiocytic sarcoma and DLBCL [4], DLBCL with myeloma [5], mantle cell lymphoma with chronic lymphocytic leukemia (CLL) [6,7], and DLBCL with Hodgkin's lymphoma [8,9], MPDs with CLL, and MPDs with hairy cell leukemia [10].…”
Section: Discussionmentioning
confidence: 99%